TuHURA Biosciences (NASDAQ:HURA – Get Free Report) was upgraded by equities researchers at RODMAN&RENSHAW to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.
Several other brokerages also recently weighed in on HURA. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a report on Thursday. They issued a “buy” rating and a $11.00 target price on the stock. Maxim Group assumed coverage on TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective on the stock.
View Our Latest Report on HURA
TuHURA Biosciences Stock Up 12.0 %
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
- Five stocks we like better than TuHURA Biosciences
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Canadian Penny Stocks: Can They Make You Rich?
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is a support level?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
